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Abstract
Background: Previous studies in experimental and human heart failure showed that nuclear factor
kappa B (NF-κB) is chronically activated in cardiac myocytes, suggesting an important involvement
of NF-κB in the cardiac remodeling process. A common insertion/deletion (-94 insertion/deletion
ATTG, rs28362491) located between two putative key promoter regulatory elements in the
NFKB1 gene was identified which seems to be the first potential functional NFKB1 genetic variation.
The main goal of the present investigation was to investigate the NFKB1 -94 insertion/deletion
ATTG polymorphism in relation to risk of dilated cardiomyopathy (DCM).
Methods: A total of 177 DCM patients and 203 control subjects were successfully investigated.
The NFKB1 -94 insertion/deletion ATTG polymorphism was genotyped by using PCR-PAGE.
Results: Genotype frequency of NFKB1 -94 insertion/deletion ATTG polymorphism in DCM
patients was significantly different from that in control subjects (P = 0.015) and the ATTG2 carrier
(ATTG1/ATTG2 + ATTG2/ATTG2) was susceptible to DCM.
Conclusion:  Our data suggested that NFKB1  -94 insertion/deletion ATTG polymorphism is
associated with DCM.
Background
Dilated cardiomyopathy (DCM), characterized by left
ventricular dilation and systolic dysfunction, is the most
common form of heart muscle disease, comprising 60%
of the cases of identified cardiomyopathy [1]. This disor-
der is clinically heterogeneous, ranging from affected indi-
viduals with clinical presentations of severe symptoms,
including heart failure and sudden death, and asympto-
matic individuals. The clinical course of DCM, almost
regardless of the underlying cause, may be progressive,
with roughly 50% of individuals reported to die within 5
years of diagnosis without transplantation [1,2]. Although
longer survival has been accomplished recently with
improved medical therapies and interventions, early
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examinations are necessary to improve the DCM progno-
sis. The etiology of DCM is multifactorial and many differ-
ent clinical conditions can lead to phenotype of DCM. It
has become evident that genetic factors play an important
role in the etiology and pathogenesis of DCM. To date,
DCM-associated mutations in many different genes have
been reported, but still these mutations explain only a
minority of the etiology of DCM [3]. Some susceptibility
genes have been shown to be associated with an increased
risk of developing a DCM. These include HLA-
DQA1*0501, HLA-DRB1*1401, exon 8 C/T of Endothe-
lin receptor A, Leu10Pro of TGF-beta1, G994T of PAF
acetyl hydrolase, MMP-3 5A/6A, and so on [4-6]. With
more knowledge about susceptibility genes and pathways
involved in DCM, strategies may emerge to reduce myo-
cyte death, and diminish myocardial fibrosis, processes
that ultimately cause the heart fail.
Clinical observations and experimental studies have dem-
onstrated that left ventricular (LV) remodeling and dila-
tion occurs with the progression of end-stage LV failure. It
has been reported that in experimental and human heart
failure, nuclear factor kappa B (NF-κB) is chronically acti-
vated in cardiac myocytes, suggesting an important
involvement of NF-κB in the cardiac remodeling process
[7]. NF-κB is a redox-sensitive transcription factor regulat-
ing a battery of inflammatory genes and it has been impli-
cated as important for initiation and progression of
pathogenesis of many autoimmune and inflammatory
diseases [8-10]. Numerous lines of investigation suggest
that NF-κB could promote tumorigenesis [11]. Cardiac-
specific expression of tumor necrosis factor (TNF) has pre-
viously been shown to produce DCM, presumably
through intact TNF-related apoptosis [12]. In endothelin-
1 deficient hearts NF-κB activity decreased, resulting in
diminution of downstream inhibitors of TNF signaling
[13]. It is apparent that the role of NF-κB in the regulation
of cardiomyocyte viability is multidimensional and might
contribute to the development of DCM.
A common insertion/deletion polymorphism (-94 inser-
tion/deletion ATTG, rs28362491) located between two
putative key promoter regulatory elements in the NFKB1
gene was identified which seems to be the first potential
functional NFKB1 genetic variation. The presence of a 4
base pair (bp) deletion resulted in the loss of binding to
nuclear proteins, leading to reduced promoter activity
[14]. A research has shown that the deletion was associ-
ated with an increased risk for an inflammatory intestinal
disorder-ulcerative colitis (US), but subsequently other
study failed to replicate this association [14-19]. Further-
more significant associations of this polymorphism with
other disease entities (type 1 diabetes, oral squamous cell
carcinoma, colorectal cancer, and melanoma) have been
reported [20-23]. However, its association with DCM is
still unclear. The main goal of the present investigation
was to determine the possible susceptibility of NFKB1 -94
insertion/deletion ATTG polymorphism on the occur-
rence of DCM.
Methods
Subjects
This study was approved by the hospital ethics committee
and all subjects gave written informed consent to partici-
pate. One hundred and seventy seven unrelated DCM
patients between September 2002 and March 2008 were
enrolled in this study. The diagnosis of DCM was made in
accordance with the revised criteria established by the
1995 World Health Organization/International Society
and Federation of Cardiology Task Force on the Classifica-
tion of Cardiomyopathy (DCM group) [2] The control
group consisted of 203 healthy subjects from a routine
health survey. All subjects were Han population living in
Sichuan province of southwest China. Patients with a his-
tory of hypertension, coronary heart disease, cardiac valve
disease, tachyarrhythmia, heavy alcohol intake, acute viral
myocarditis, systemic diseases of putative autoimmune
origin, or skeletal myopathies were intentionally
excluded.
Determination of genotypes
Genomic DNA of each individual was extracted from 200
μl EDTA-anticoagulated peripheral blood samples by a
DNA isolation kit from Bioteke (Peking, China) and the
procedure was performed according to instruction man-
ual. The polymerase chain reaction (PCR)-polyacrylamide
gel electrophoresis (PAGE) method was used to genotype
the -94 insertion/deletion ATTG polymorphisms of
NFKB1. DNA fragments containing the polymorphism
were amplified and the primer sequences were: F 5'-tggac-
cgcatgactctatca-3', R 5'-ggctctggcttcctagcag-3'. PCR reac-
tion was performed in a total volume of 25 μl, including
2.5 μl 10× PCR buffer, 1.5 mmol/L MgCl2, 0.15 mmol/L
dNTPs, 0.5 μmol/L each primer, 100 ng of genomic DNA
and 1 U of Tag DNA polymerase. The PCR conditions
were 94°C for 4 min, followed by 32 cycles of 30 s at
94°C, 30 s at 64°C and 30 s at 72°C, with a final elonga-
tion at 72°C for 10 min. 3 μl PCR products were separated
by a 6% polyacrylamide gel and staining with 1.5 g/L
argent nitrate. Allele (ATTG)1 yield a 154 bp band and
allele (ATTG)2 yield a 158 bp band. About 20% of the
samples were randomly selected to perform the repeated
assays and the results were 100% concordant.
Statistical analysis
All data analyses were carried out using SPSS 13.0 statisti-
cal software. Allelic and genotype frequencies of NFKB1
gene -94 insertion/deletion ATTG polymorphism were
obtained by directed counting and Hardy-Weinberg equi-
librium were evaluated by chi-square test. Odds ratioBMC Medical Genetics 2009, 10:47 http://www.biomedcentral.com/1471-2350/10/47
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(OR) and respective 95% confidence intervals were
reported to evaluate the effects of any difference between
allelic and genotypes distribution. Probability values of
0.05 or less were regarded as statistically significant in
DCM patients compared to healthy controls.
Results
Genotype distributions had no deviation from Hardy-
Weinberg equilibrium both in patients and controls. Dif-
ferences in allelic and genotype distribution of NFKB1
gene -94 insertion/deletion ATTG polymorphism were
tested between DCM patients and controls, and observed
differences are presented in Table 1.
The overall genotype frequency of DCM patients was sig-
nificantly different from that of controls. The frequency
for ATTG1/ATTG1 genotype was slightly overrepresented
in controls (P = 0.004, OR = 2.463, 95%CI = 1.321–4.592
for ATTG1/ATTG1 vs. ATTG1/ATTG2 comparison, and P =
0.023, OR = 2.103, 95%CI = 1.101–4.018 for ATTG1/
ATTG1 vs. ATTG2/ATTG2 comparison, respectively). Fur-
thermore, the P  value and OR were 0.005 and 2.304,
respectively, ATTG1/ATTG2  + ATTG2/ATTG2  vs. ATTG1/
ATTG1 comparison, indicating that ATTG2 carrier (ATTG1/
ATTG2 + ATTG2/ATTG2) was susceptible to DCM. The fre-
quency of allele ATTG2 in DCM patients was higher than
that in control subjects (62.7% vs. 57.1%), but is not sta-
tistically significant (P = 0.118).
Discussion
Genetic factors are known to play an important role in the
etiology of DCM. The first DCM-associated mutation, in
the dystrophin gene, was described in 1993 [24,25]. The
genetic of DCM have been under intensive investigation
lately and the knowledge on the genetic basis of DCM has
increased rapidly. To date, DCM-associated mutations in
many different genes with subsequent alterations in pro-
tein structure have been reported, but these mutations
explain only a minority of the etiology of DCM [3]. Some
susceptibility genes have also been shown to be associated
with an increased risk of developing a DCM.
NF-κB was discovered by Baltimore and coworkers in
1986 as a factor in the nucleus of B cells that binds to the
enhancer of the kappa light chain of immunoglobulin
[11,26]. The transcription of many genes for immune
response, cell adhesion, differentiation, proliferation,
angiogenesis and apoptosis are regulated by NF-κB. It is
just this characteristic that makes NF-κB the crucial point
of convergence of a number of stimuli that can influence
different aspects of cellular homeostasis [27]. Inappropri-
ate activation of NF-κB can mediate inflammation and
tumorigenesis. How NF-κB activation mediates tumori-
genesis and inflammation has been widely studied during
the past decade. Most inflammatory agents mediate their
effects through the activation of NF-κB and it is sup-
pressed by anti-inflammatory agents. Most carcinogens
and tumor promoters activated NF-κB, whereas chemo-
preventive agents suppress it [11]. NF-κB is rarely found to
be constitutively active in normal cells except for prolifer-
ating T cells, B cells, thymocytes, monocytes, and astro-
cytes, while it is constitutively active in most tumor cell
lines [11,23,27]. However, the proposal that NF-κB leads
to the onset of cancer has been changed by the evidence
that, for skin cancer, NF-κB activation has been postulated
as a safeguard against cancer [27,28]. Further studies
could help to figure out the molecular mechanisms that
dictate the pro-oncogenic or anti-oncogenic activity of
NF-κB.
The -94 insertion/deletion ATTG polymorphism was
identified in a study sequenced the NFKB1 promoter in 10
inflammatory bowel disease and 2 controls, and the
ATTG1 allele was more frequent in ulcerative colitis than
that in controls in the following study. The in vitro pro-
moter expression studies suggest that the ATTG1 allele
may result in relatively decreased NFKB1  message and
hence decreased p50/p105 NF-κB protein production
[14]. The association between -94 insertion/deletion
ATTG polymorphism and susceptibility to ulcerative coli-
tis was confirmed in another study, but data were incon-
sistent and this association could not be replicated in
different population [16,17,29].
Table 1: The allelic and genotype distributions of NFKB1 polymorphism among patients and controls
Variables Patients(n = 177) Controls(n = 203) p OR 95% CI
NFKB1-94 genotype ATTG1/ATTG1 18(10.2) 42(20.7) - 1 -
ATTG1/ATTG2 95(53.7) 90(44.3) 0.004 2.463 1.321–4.592
ATTG2/ATTG2 64(36.1) 71(35.0) 0.023 2.103 1.101–4.018
ATTG1/ATTG2+ATTG2/ATTG2 versus ATTG1/ATTG1 0.005 2.304 1.272–4.174
ATTG1/ATTG1+ATTG1/ATTG2 versus ATTG2/ATTG2 0.810 1.053 0.691–1.604
NFKB1-94
allele
ATTG1 132(37.3) 174(42.9) 0.118 1.261 0.942–1.688
ATTG2 222(62.7) 232(57.1)
Note: Bold-faced values indicate significant difference at the 5% level.BMC Medical Genetics 2009, 10:47 http://www.biomedcentral.com/1471-2350/10/47
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Given the considerable important role of NF-κB pathway
involved in initiation and progression of pathogenesis in
disease, we investigated the association between -94 inser-
tion/deletion ATTG polymorphism and susceptibility to
DCM. The present study shows that the allelic frequency
for NFKB1  gene -94 insertion/deletion ATTG polymor-
phism in DCM patients is not significantly different from
that of controls. However, the genotype frequency distri-
bution in DCM patients was significantly different from
that of controls. The frequency of the ATTG1/ATTG1 geno-
type of NFKB1 gene -94 insertion/deletion ATTG poly-
morphism in controls was significantly higher that in
DCM patients. We conducted comparison between
ATTG1/ATTG1  and (ATTG1/ATTG2+ATTG2/ATTG2) in
DCM patients and controls, and further significant differ-
ence was observed (p = 0.005). These results indicated that
ATTG2 carrier (ATTG1/ATTG2 + ATTG2/ATTG2) was sus-
ceptible to DCM. The allelic distribution between DCM
patients and controls was different, although not statisti-
cally significant (p = 0.118), and the frequency for ATTG2
allele in DCM patients is higher than that in controls,
although not statistically significant, also indicating that
ATTG2 allele might be a risk factor for the susceptibility to
DCM.
The role of NF-κB in heart has been extensively studied by
many authors [10]. Its role in the regulation of cardiomy-
ocyte viability is multidimensional, because it was
believed to activate cell-death pathway and it can also pro-
tect cells from death. In hearts subjected to in vivo infarc-
tion, NF-κB-activation is biphasic, peaking after 15 min
and 3 h reperfusion, respectively. NF-κB might play a det-
rimental role during reperfusion and inhibition of leuko-
cyte adhesion, cytokines, and chemokines which are
regulated by NF-κB during reperfusion protects the heart
against reperfusion injury [10,30]. A detrimental role of
NF-κB-activation in cardiac allograft rejection has been
suggested, as pharmacological inhibition of NF-κB pro-
longs survival of heterotopic transplants [31]. In athero-
sclerotic lesions the NF-κB-regulated inflammatory
mediators such as cytokines, inducible NO synthase and
leukocyte adhesion molecules have been detected, and
mice deficient in NF-κB signaling exhibit reduced fatty-
streak formation when fed a fatty diet [32,33]. Although
the functional consequences are as yet undetermined,
both systemic and cardiac activation of NF-κB have been
found in unstable coronary syndromes. The present study
shows that the genotype distribution of NFKB1 gene -94
insertion/deletion ATTG polymorphism in DCM patients
is significantly different from that in control subjects, and
(ATTG1/ATTG2+ATTG2/ATTG2) genotype frequency is
higher in DCM patients than that in control subjects. Con-
sidering that the ATTG1 allele may result in decreased
NFKB1  message and p50/p105 NF-κB protein produc-
tion, a detrimental role of NF-κB-activation in the initia-
tion and progression of pathogenesis in DCM can be
presumed and much further work will be needed for a
complete understanding of its mechanism. The main lim-
itation of the present study is the relatively small size of
the study population and the lack of replication of the sig-
nificant association in a second independent cohort of
DCM patients.
Conclusion
From this study we conclude that the NFKB1 -94 inser-
tion/deletion ATTG polymorphism is significantly associ-
ated with DCM. The genotype frequency of (ATTG1/
ATTG2+ATTG2/ATTG2) is significantly overrepresented in
DCM patients, indicating that ATTG2 carriers are associ-
ated with the increased risk of DCM. However, additional
studies in a larger number of DCM patients and in differ-
ent populations could help to establish the true signifi-
cance of this association.
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